Skip to content

Clinical efficacy of Jiannao Bushen Wan in the treatment of cognitive impairment

Study on the efficacy and mechanism of Jiannao Bushen Wan on cognitive impairment

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400082965
Enrollment
Unknown
Registered
2024-04-11
Start date
2024-04-02
Completion date
Unknown
Last updated
2025-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitive impairment

Interventions

Drug group:Jiannao Bushen Wan
Placebo group:Jiannao Bushen Wan placebo
Chinese medicine control group:Ginkgo tablet
Western medicine control group:Donepezil

Sponsors

The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Age > 50 years, years of formal education >= 6, Normal vision and hearing; ability to complete neuropsychological assessments; 2. Cognitive impairment: includes patients or their informants reporting cognitive decline with objective evidence of cognitive impairment (including global cognition, memory, executive function, visuospatial ability, or language, as evidenced by scores on at least one cognitive domain test that is less than 1.5 standard deviations below the mean for the average elderly population); 3. TCM syndrome differentiation is kidney essence deficiency and (or) spleen and kidney deficiency.

Exclusion criteria

Exclusion criteria: 1.The patients were clinically diagnosed with moderate to severe dementia (by DSM-IV and NINCDS-ADRDA diagnostic criteria); 2.Confirmed diagnosis of a significant neuropsychiatric disorder with unstable or severe cardiac, pulmonary, hepatic, renal, or haematopoietic disorders; 3.Unable to complete neuropsychological tests and scale assessment due to other physical and mental diseases; 4.Have participated in or are participating in other drug trials within three months before enrollment; 5.Poor compliance, severe disease or life-threatening, and the expected survival time is less than one year, so the treatment cannot be completed.

Design outcomes

Primary

MeasureTime frame
Auditory Verbal Learning Test;Mini-mental State Examination;

Secondary

MeasureTime frame
TCM syndrome score;Activity of Daily Living Scale;Rey-Osterrieth Complex Figure Test;Trail Making Test;Stroop Color Word Test;Clock Drawing Test;Symbol Digit Modalities Test;Verbal Fluency Test;Boston Naming Test;Self-Rating Anxiety Scale;Geriatric Depression Scale;Pittsburgh sleep quality index;Magnetic resonance imaging (Structural MRI and diffusion tensor imaging DTI);

Countries

China

Contacts

Public ContactDao junxie

The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine

daojunxie81@163.com+86 138 6614 1316

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026